Tysabri News
Most Popular Tysabri Story
Tysabri label change could add $1B to sales
Biogen Idec ($BIIB) has pulled off a big coup in personalized medicine. The multiple sclerosis drug Tysabri has long been weighed down by a well-known safety risk: It's linked with a potentially Read more...
Latest Headlines
- January 23, 2012
- September 6, 2011
- April 25, 2011
- April 21, 2011
- January 12, 2011
- December 22, 2010
- December 17, 2010
- April 8, 2010
- March 25, 2010
- March 1, 2010
- February 8, 2010
- January 25, 2010
- January 13, 2010
- November 23, 2009
- November 9, 2009
- October 30, 2009
- October 28, 2009
- October 26, 2009
- September 29, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
